FRAPEYQUEST: French Translation and Validation of the PEYronie's Disease QUESTionnaire
Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT05768867
Collaborator
(none)
30
1
23.9
1.3
Study Details
Study Description
Brief Summary
This study is a prospective cohort dedicated to peyronie's disease. The aim is to validate the french translation of the peyronie's disease questionnaire. The primary endpoint is the response rate to the questionnaire.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
French Translation and Validation of the PEYronie's Disease QUESTionnaire
Actual Study Start Date
:
Mar 6, 2023
Anticipated Primary Completion Date
:
Mar 1, 2024
Anticipated Study Completion Date
:
Mar 1, 2025
Outcome Measures
Primary Outcome Measures
- Rate of responses [Day 0]
Response rate to the online questionnaire.
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Adult patient with Peyronie's Disease clinically diagnosed during a consultation, with palpation of at least one plaque
Exclusion Criteria:
-
Patient refusing to participate
-
Patient with difficulties in understanding the French language.
-
Protected persons referred to in articles L.1121-6 to L.1121-8 of the public health code
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Toulouse Hospital | Toulouse | France |
Sponsors and Collaborators
- University Hospital, Toulouse
Investigators
- Principal Investigator: Eric Huyghe, MD, University Hospital, Toulouse
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT05768867
Other Study ID Numbers:
- RC31/23/0012
- 2023-A00219-36
First Posted:
Mar 14, 2023
Last Update Posted:
Mar 16, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: